Mithrl Raises $20M to Expand Deployment of Its Biomedical World Model Across Biopharma

- Friends! Mithrl pocketed $20M (Obvious Ventures leading) to push its biomedical world model deeper into biopharma pipelines. Founder Vivek Adarsh lost his grandfather to kidney disease 15 years back — no approved drugs existed then — and built Mithrl-1 to cut idea-to-IND timelines by half. The odd charm: its agents reason only over validated biology, not open-web guesswork, burning 45% fewer tokens than vanilla frontier workflows. Deployed inside each client's environment — like a licensed corpse carrying its own medical chart — the platform cites sources and confidence scores with every hypothesis. It's already backed half a dozen customer patent filings and claims 0.96 scientific correctness on expert-rated benchmarks. "The industry is cracking under the weight of hypotheses it can't triage," Adarsh says. Don't hiss at the doctor — this one shows its work.